4.6 Article

Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation

Journal

SUPPORTIVE CARE IN CANCER
Volume 28, Issue 3, Pages 1223-1231

Publisher

SPRINGER
DOI: 10.1007/s00520-019-04932-9

Keywords

Symptoms; Electronic symptom reporting; Patient-reported outcomes; Autologous stem cell transplantation; Allogeneic stem cell transplantation; Cancer

Funding

  1. National Institutes of Nursing Research [T32 NR00709] Funding Source: Medline
  2. NCI NIH HHS [5K12CA120780-07, K12 CA120780, P30-CA-016086, P30 CA016086] Funding Source: Medline
  3. NCRR NIH HHS [UL1 RR025747] Funding Source: Medline
  4. University Cancer Research Fund [UL1RR025747] Funding Source: Medline

Ask authors/readers for more resources

Purpose Patients undergoing a hematopoietic stem cell transplantation (HCT) have varied symptoms during their hospitalization. This study examined whether daily symptom reporting (with electronic patient-reported outcomes [PROs]) in an inpatient bone marrow transplant clinic reduced symptom burden on post-transplant days +7, +10, and +14. Methods A prospective, single-institution 1:1 pilot randomized, two-arm study recruited HCT patients. HCT inpatients (N = 76) reported daily on 16 common symptoms using the PRO version of the Common Terminology for Adverse Events (PRO-CTCAE). Fisher's exact test was used to examine differences in the proportion of patients reporting individual symptoms. Multivariable linear regression modeling was used to examine group differences in peak symptom burden, while controlling for symptom burden at baseline, age, comorbidity, and transplantation type (autologous or allogeneic). Results HCT patients receiving the PRO intervention also experienced lower peak symptom burden (average of 16 symptoms) at days +7, +10, and +14 (10.4 vs 14.5, p = 0.03). Conclusions Daily use of electronic symptom reporting to nurses in an inpatient bone marrow transplant clinic reduced peak symptom burden and improved individual symptoms during the 2 weeks post-transplant. A multi-site trial is warranted to demonstrate the generalizability, efficacy, and value of this intervention.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available